Tranexamic acid and in-hospital mortality in adults with type 2 diabetes: A case series
Published
March 21, 2025
Paper ID
PAP-000161
Status
Published
DOI
10.65712/tmj.test000419
Advance Services
Abstract
Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: in-hospital mortality occurred in 6% of the intervention group versus 19% of controls. Serious adverse events were rare and similar between groups. Conclusion: Residual confounding cannot be excluded.
Introduction
in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes. The cost of in-hospital mortality to health systems is substantial.
Guidelines make only a weak recommendation on tranexamic acid. The cost of in-hospital mortality to health systems is substantial.
Materials and Methods
The primary outcome was in-hospital mortality, assessed blind to allocation. We conducted a case series across 1 centres between 2019 and 2022. We conducted a case series across 8 centres between 2016 and 2024.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was in-hospital mortality, assessed blind to allocation.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was in-hospital mortality, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.73 (95% CI 0.43 to 0.80).
Effects were consistent across prespecified subgroups. 4412 participants were included (median age 69 years). 518 participants were included (median age 55 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Intervention | 231 | 74 | 33.1 |
| Centre B | 97 | 105 | 6.3 |
| Age ≥ 65 | 530 | 78 | 1.9 |
| Centre A | 362 | 119 | 20.1 |
| Centre B | 830 | 16 | 40.8 |
| Age < 65 | 224 | 86 | 2.4 |
| Intervention | 97 | 76 | 36.3 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. 3132 participants were included (median age 30 years). Serious adverse events were rare and similar between groups.
Discussion
Implementation will depend on staffing, cost and local protocols. Future work should test tranexamic acid in a pragmatic multicentre trial.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Conclusions
Tranexamic acid is a reasonable option for adults with type 2 diabetes to improve in-hospital mortality.
References
1. Okafor F, Tanaka D, et al. Home-based cardiac rehabilitation and health-related quality of life. BMJ. 2024;311(1):777-1703.
2. Silva E, Schmidt M, et al. Tranexamic acid and post-operative delirium. JAMA. 2011;325(7):303-986.
3. Andersen C, Novak M, et al. Machine-learning triage and time to diagnosis. Crit Care Med. 2017;86(2):636-982.
4. Rahman M, Kaur K, et al. SGLT2 inhibitors and glycaemic control. Lancet. 2012;134(11):658-1289.
5. Ibrahim E, Ibrahim N, et al. An enhanced recovery pathway and ventilator-free days. Eur Heart J. 2022;208(4):335-910.
6. Yilmaz K, Okafor Q, et al. An antibiotic stewardship programme and chronic pain scores. BMC Med. 2019;390(6):232-1396.
7. Larsen S, Nasser D, et al. Continuous glucose monitoring and medication adherence. Eur Heart J. 2012;189(11):151-1592.
8. Tanaka U, Ahmed K, et al. A sepsis alert system and glycaemic control. Crit Care Med. 2024;210(12):689-1782.
Appendices
Ethics approval: IRB-9729.